Cart (Loading....) | Create Account
Close category search window

Targeted delivery of vascular endothelial growth factor to enhance the stem cell therapy in treating myocardial infarction in rats

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

4 Author(s)
Yuan Tang ; Dept. of Mech. Eng., Temple Univ., Philadelphia, PA, USA ; Curran, E. ; Kiani, M.F. ; Bin Wang

The stem cell therapy to treat myocardial infarction (MI) has shown disappointed results largely due to the poor survival of transplanted stem cells in the MI region. We propose a combination therapy by targeted delivery of a proangiogenic compound, vascular endothelial growth factor (VEGF), to MI region to improve the micro-environment, which may enhance the survival of transplanted stem cells, and further improve the cardiac function. In this study, P-selectin conjugated immunoliposomes containing VEGF were given to the MI rats through tail vein injection immediately after surgery. Mesenchymal stem cells (MSCs) were transplanted to the MI region one week later. Left ventricular percent fractional shortening were measured 1 week and 4 weeks post MI using echocardiography. Results indicate that MI rats with no treatment lost 8% contractility (~40% of its heart function) from 1 week to 4 weeks post-MI. Either targeted VEGF or MSCs treatment alone can slow down the loss by half to 4%. The combination of targeted VEGF and MSCs treatment further decreased the contractility loss to 0.7%. In conclusion, the combination treatment of targeted VEGF and MSCs results in a larger recovery in cardiac function compared to either targeted VEGF or stem cell treatment alone.

Published in:

Bioengineering Conference (NEBEC), 2012 38th Annual Northeast

Date of Conference:

16-18 March 2012

Need Help?

IEEE Advancing Technology for Humanity About IEEE Xplore | Contact | Help | Terms of Use | Nondiscrimination Policy | Site Map | Privacy & Opting Out of Cookies

A not-for-profit organization, IEEE is the world's largest professional association for the advancement of technology.
© Copyright 2014 IEEE - All rights reserved. Use of this web site signifies your agreement to the terms and conditions.